Elizaveta I. Kotlyarevskaya

Elizaveta I. Kotlyarevskaya

Auto-generated profile, based on publicly available information

Elizaveta I. Kotlyarevskaya

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Closed access
ABAzamat Baymukanov
Azamat Baymukanov
YWYuliya Weissman
Yuliya Weissman
EKE. I. Kotlyarevskaya
E. I. Kotlyarevskaya
AMA. V. Melekhov
A. V. Melekhov
Transthyretin (ATTR) amyloidosis is a progressive disease that can present as isolated cardiac involvement or as a combination with systemic manifestations, including polyneuropathy, gastrointestinal tract disorders, and ophthalmopathy. The disease is associated with the deposition of unstable breakdown products of transthyretin tetramers, a plasma protein responsible for transporting thyroxine and retinol. ATTR is most commonly hereditary (ATTRm/ATTRv), caused by mutations in the transthyretin gene, but it can also occur in an acquired, non-hereditary “wild-type” form (ATTRwt), which develops in older adults. Cardiac involvement in ATTR amyloidosis resembles hypertrophic or restrictive cardiomyopathy, manifesting as symptoms of heart failure, rhythm disorders, and conduction abnormalities. Diagnosis is challenging due to the rarity of the disease, nonspecific symptoms, and the difficulties of performing endomyocardial biopsy. The verification of the diagnosis increasingly relies on modern imaging methods such as gadolinium-enhanced magnetic resonance imaging and technetium-99m pyrophosphate myocardial scintigraphy. The presented clinical case describes a 56-year-old patient with amyloid cardiomyopathy, which manifested as a combination of progressive rhythm and conduction disturbances (atrial fibrillation, trifascicular block, pauses up to 4,7 seconds, and runs of ventricular tachycardia) against the background of gradually decreasing left ventricular ejection fraction and marked diastolic dysfunction. These clinical syndromes necessitated the exclusion of secondary causes of myocardial involvement. The diagnosis was confirmed without biopsy – through the use of modern imaging techniques, including contrast-enhanced cardiac MRI and 99mTc-pyrophosphate scintigraphy, in accordance with current recommendations. This case illustrates the possibility of early detection and successful treatment of ATTRwt amyloidosis using advanced diagnostic methods in real-world clinical practice. These methods help refine the disease’s prevalence, improve diagnostic accuracy, and ensure timely treatment, significantly influencing the prognosis and quality of life.

15 January 2025 in The Clinician
Verified
Journal Article
Open access
PDF file
YWYuliya Weissman
Yuliya Weissman
ABAzamat Baymukanov
Azamat Baymukanov
AEA. A. Evmenenko
A. A. Evmenenko
IBI. A. Bulavina
I. A. Bulavina
MYM. V. Yunyaeva
M. V. Yunyaeva
ЮВЮ. Д. Вайсман
Ю. Д. Вайсман
Aim. To compare patients with bradyarrhythmias and obstructive sleep apnea (OSA) and patients without OSA; to study the predictive capabilities of questionnaires in OSA screening.Material and methods. The study included 134 patients with bradyarrhythmias hospitalized for pacemaker implantation or pacemaker replacement. The median age was 67.5 years (interquartile range 59 to 72 years). Sleep apnea screening was performed using the Berlin questionnaire, the STOP-BANG sleep apnea risk scale, and the Epworth sleepiness scale. All patients underwent blood tests and instrumental examinations (respiratory monitoring and echocardiography).Results. Patients with OSA were older (68 years versus 64 years; p = 0.032), had a larger waist circumference (116 cm versus 108 cm; p = 0.044), and body mass index (33.7 kg/m2 versus 31.03 kg/m2; p = 0.016) compared to patients without OSA. The Berlin questionnaire (area under the curve (AUC) 0.79; sensitivity 92 %, specificity 38 %; p 0.0001) and the STOP-BANG risk scale (AUC 0.75; sensitivity 82 %, specificity 23 %; p 0.0001) had a high predictive power to identify sleep apnea while the Epworth sleepiness scale had a low predictive power (AUC 0.463; sensitivity 12 %, specificity 85 %). According to laboratory and instrumental data, patients with sleep apnea had significantly higher C-reactive protein levels (7.17 mg/L versus 1.73 mg/L; p = 0.012) and more frequently had interventricular septal hypertrophy (12 mm versus 10 mm; p = 0.02). Third-degree atrioventricular block was significantly more common in patients with sleep apnea (17.91 % versus 5.97 %; odds ratio 0.363; 95 % confidence interval 0.131–1.001; p = 0.045). In patients with sleep apnea, cardiac pacing for more than 5 years was more common (11.94 % versus 4.48 %; odds ratio 0.35; 95 % confidence interval 0.116–1.054; p = 0.049).Conclusion. High frequency of OSA was observed in patients with bradysystolic heart rate. The Berlin questionnaire and the STOP-BANG sleep apnea risk scale can be used to screen for OSA in patients with bradyarrhythmias. Elevated C-reactive protein levels and interventricular septal hypertrophy accentuate the importance of early diagnosis and treatment of OSA for improved prognosis.

23 September 2025 in Russian Medicine
Verified
Journal Article
Open access
PDF file
EKElizaveta I. Kotlyarevskaya
Elizaveta I. Kotlyarevskaya
RSRim Albertovich Sadrutdinov
Rim Albertovich Sadrutdinov
EDElnara Ferrukhovna Dadashova
Elnara Ferrukhovna Dadashova
ABAzamat Baymukanov
Azamat Baymukanov
AKAlexander Romanovich Katanaev
Alexander Romanovich Katanaev
GGGennady Efimovich Gendlin
Gennady Efimovich Gendlin
Implantable intracardiac devices, including permanent pacemakers, cardioverter-defibrillators, and cardiac resynchronization therapy systems, have become firmly established in clinical practice and demonstrated efficacy in improving prognosis in patients with bradyarrhythmias, high risk of sudden cardiac death, and chronic heart failure. However, with the increasing number of implantations, late complications are attracting more attention, particularly tricuspid regurgitation associated with implanted intracardiac leads. It has been shown that lead-associated tricuspid regurgitation may be linked to worsening heart failure symptoms, increased hospitalization rates, and reduced survival. Nevertheless, the pathophysiologic mechanisms of this condition, its clinical course, and diagnostic approaches remain insufficiently standardized, and current clinical guidelines lack clear management algorithms. According to published data, the prevalence of tricuspid regurgitation after lead implantation ranges from 7% to 39%, reflecting heterogeneity across reports and the absence of unified diagnostic criteria. This considerably complicates assessment of the true prevalence and clinical significance of this complication. An additional challenge is the choice of treatment strategy, especially when deciding on transvenous lead extraction or surgical correction. Thus, an individualized and multidisciplinary approach is required for each patient, and further investigations are needed to develop consistent clinical recommendations.

8 March 2025 in Journal of Arrhythmology
Verified
Journal Article
Open access
PDF file
ABAzamat Baymukanov
Azamat Baymukanov
EKE. I. Kotlyarevskaya
E. I. Kotlyarevskaya
AMA. V. Melekhov
A. V. Melekhov
GGG. E. Gendlin
G. E. Gendlin
Supraventricular premature beats (PACs) are common in the general population. Previously considered a benign ECG finding with little clinical significance. However, increasing evidence now suggests a positive correlation between the frequency of PACs and the risk of developing atrial fibrillation, ischemic stroke, transient ischemic attack, and all-cause mortality. This has highlighted the importance of determining the clinical significance of PACs and the management strategies for affected patients.